Liver Transplantation in HIV-Infected Recipients

ABSTRACT

Although human immunodeficiency virus (HIV)-infected patients are living longer and dying less often from complications related to acquired immunodeficiency syndrome (AIDS), they are experiencing significant morbidity and mortality related to end-stage liver disease. Advances in the management of HIV disease have made it difficult to continue denying transplantation to this population based upon futility arguments alone. Patient and graft survival rates in HIV-infected study subjects appear similar to those in large transplant databases. There are no reports suggesting significant HIV disease progression. There are substantial interactions between immunosuppressants and antiretroviral drugs that require careful monitoring and dose adjustment. The evaluation and management of HIV-infected transplant candidates and recipients require excellent communication among a multidisciplinary team and the primary HIV care provider. It is critical that HIV clinicians and hepatologists are aware that liver transplantation is an option for HIV-infected patients at many transplant centers as delays in referral result in unnecessary mortality during the pretransplantation evaluation process.

KEYWORDS

Transplantation - human immunodeficiency virus - hepatitis - end-stage liver disease

REFERENCES

• 1 Puoti M, Spinetti A, Ghezzi A et al.. Mortality from liver disease in patients with HIV infection: a cohort study.  J Acquir Immune Defic Syndr. 2000;  24 211-217
• 2 Martin-Carbonero L, Soriano V, Valencia E, Garcia-Samaniego J, Lopez M, Gonzalez-Lahoz J. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients.  AIDS Res Hum Retroviruses. 2001;  17 1467-1471
• 3 Puoti M, Bruno R, Soriano V et al.. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome.  AIDS. 2004;  18 2285-2293
• 4 Rosenthal E, Poiree M, Pradier C et al.. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study).  AIDS. 2003;  17 1803-1809
• 5 Mocroft A, Soriano V, Rockstroh J et al.. Is there evidence for an increase in the death rate from liver-related disease in patients with HIV?.  AIDS. 2005;  19 2117-2125
• 6 Ragni M V, Eghtesad B, Schlesinger K W, Dvorchik I, Fung J J. Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease.  Liver Transpl. 2005;  11 1425-1430
• 7 Gebo K A, Fleishman J A, Moore R D. Hospitalizations for metabolic conditions, opportunistic infections, and injection drug use among HIV patients: trends between 1996 and 2000 in 12 states.  J Acquir Immune Defic Syndr. 2005;  40 609-616
• 8 Bica I, McGovern B, Dhar R et al.. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection.  Clin Infect Dis. 2001;  32 492-497
• 9 Cacoub P, Geffray L, Rosenthal E, Perronne C, Veyssier P, Raguin G. Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine/Infectious Diseases, in 1995 and 1997.  Clin Infect Dis. 2001;  32 1207-1214
• 10 Jain M K, Skiest D J, Cloud J W, Jain C L, Burns D, Berggren R E. Changes in mortality related to human immunodeficiency virus infection: comparative analysis of inpatient deaths in 1995 and in 1999-2000.  Clin Infect Dis. 2003;  36 1030-1038
• 11 Louie J K, Hsu L C, Osmond D H, Katz M H, Schwarcz S K. Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Francisco, 1994-1998.  J Infect Dis. 2002;  186 1023-1027
• 12 Monga H K, Rodriguez-Barradas M C, Breaux K et al.. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection.  Clin Infect Dis. 2001;  33 240-247
• 13 Qurishi N, Kreuzberg C, Luchters G et al.. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection.  Lancet. 2003;  362 1708-1713
• 14 Ragni M V, Belle S H. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection.  J Infect Dis. 2001;  183 1112-1115
• 15 Thio C L, Seaberg E C, Skolasky Jr R et al.. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS).  Lancet. 2002;  360 1921-1926
• 16 Stock P G. Rapid deterioration of HIV co-infected patients waiting for liver transplantation is not predicted by MELD.  Liver Transpl. 2005;  11 1315-1317
• 17 Staples Jr C T, Rimland D, Dudas D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta VA. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival [comments].  Clin Infect Dis. 1999;  29 150-154
• 18 Soriano V, Garcia-Samaniego J, Valencia E, Rodriguez-Rosado R, Munoz F, Gonzalez-Lahoz J. Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users.  Eur J Epidemiol. 1999;  15 1-4
• 19 Palella Jr F J, Delaney K M, Moorman A C et al.. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators [comments].  N Engl J Med. 1998;  338 853-860
• 20 Feinberg M B. Changing the natural history of HIV disease.  Lancet. 1996;  348 239-246
• 21 Kaplan J E, Hanson D, Dworkin M S et al.. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy.  Clin Infect Dis. 2000;  30(suppl 1) S5-S14
• 22 Halpern S D, Ubel P A, Caplan A L. Solid-organ transplantation in HIV-infected patients.  N Engl J Med. 2002;  347 284-287
• 23 Roland M E, Havlir D V. Responding to organ failure in HIV-infected patients.  N Engl J Med. 2003;  348 2279-2281
• 24 Roland M E, Lo B, Braff J, Stock P G. Key clinical, ethical, and policy issues in the evaluation of the safety and effectiveness of solid organ transplantation in HIV-infected patients.  Arch Intern Med. 2003;  163 1773-1778
• 25 Thomas D L, Cannon R O, Shapiro C N, Hook III E W, Alter M J, Quinn T C. Hepatitis C, hepatitis B, and human immunodeficiency virus infections among non-intravenous drug-using patients attending clinics for sexually transmitted diseases.  J Infect Dis. 1994;  169 990-995
• 26 Ockenga J, Tillmann H L, Trautwein C, Stoll M, Manns M P, Schmidt R E. Hepatitis B and C in HIV-infected patients: prevalence and prognostic value.  J Hepatol. 1997;  27 18-24
• 27 Newell A, Nelson M. Infectious hepatitis in HIV-seropositive patients.  Int J STD AIDS. 1998;  9 63-69
• 28 Zylberberg H, Pol S. Reciprocal interactions between human immunodeficiency virus and hepatitis C virus infections.  Clin Infect Dis. 1996;  23 1117-1125
• 29 Soto B, Sanchez-Quijano A, Rodrigo L et al.. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis [comments].  J Hepatol. 1997;  26 1-5
• 30 Wright T L, Hollander H, Pu X et al.. Hepatitis C in HIV-infected patients with and without AIDS: prevalence and relationship to patient survival.  Hepatology. 1994;  20 1152-1155
• 31 Sanchez-Quijano A, Andreu J, Gavilan F et al.. Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C.  Eur J Clin Microbiol Infect Dis. 1995;  14 949-953
• 32 Piroth L, Duong M, Quantin C et al.. Does hepatitis C virus co-infection accelerate clinical and immunological evolution of HIV-infected patients?.  AIDS. 1998;  12 381-388
• 33 Zylberberg H, Pialoux G, Carnot F, Landau A, Brechot C, Pol S. Rapidly evolving hepatitis C virus-related cirrhosis in a human immunodeficiency virus-infected patient receiving triple antiretroviral therapy.  Clin Infect Dis. 1998;  27 1255-1258
• 34 Vento S, Garofano T, Renzini C, Casali F, Ferraro T, Concia E. Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination therapy [letter].  AIDS. 1998;  12 116-117
• 35 Saves M, Vandentorren S, Daucourt V et al.. Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. Groupe Epidemiologie Clinique de Sida en Aquitaine (GECSA).  AIDS. 1999;  13 F115-F121
• 36 Puoti M, Gargiulo F, Roldan E Q et al.. Liver damage and kinetics of hepatitis C virus and human immunodeficiency virus replication during the early phases of combination antiretroviral treatment.  J Infect Dis. 2000;  181 2033-2036
• 37 Carr A, Morey A, Mallon P, Williams D, Thorburn D R. Fatal portal hypertension, liver failure, and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidaemia.  Lancet. 2001;  357 1412-1414
• 38 Chariot P, Drogou I, de Lacroix-Szmania I et al.. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion.  J Hepatol. 1999;  30 156-160
• 39 Martinez E, Blanco J L, Arnaiz J A et al.. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy.  AIDS. 2001;  15 1261-1268
• 40 McCaughan G W, Spencer J, Koorey D et al.. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin.  Liver Transpl Surg. 1999;  5 512-519
• 41 Thorne C, Newell M L. The safety of antiretroviral drugs in pregnancy.  Expert Opin Drug Saf. 2005;  4 323-335
• 42 Stern J O, Robinson P A, Love J, Lanes S, Imperiale M S, Mayers D L. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients.  J Acquir Immune Defic Syndr. 2003;  34(suppl 1) S21-S33
• 43 Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Panel on clinical practices for treatment of HIV infection convened by the Department of Health and Human Services (DHHS). October 6, 2005
• 44 Sheppard H W, Ascher M S. The natural history and pathogenesis of HIV infection.  Annu Rev Microbiol. 1992;  46 533-564
• 45 Molossi S, Clausell N, Sett S, Rabinovitch M. ICAM-1 and VCAM-1 expression in accelerated cardiac allograft arteriopathy and myocardial rejection are influenced differently by cyclosporine A and tumour necrosis factor-alpha blockade.  J Pathol. 1995;  176 175-182
• 46 Groux H, Torpier G, Monte D, Mouton Y, Capron A, Ameisen J C. Activation-induced death by apoptosis in CD4 + T cells from human immunodeficiency virus-infected asymptomatic individuals.  J Exp Med. 1992;  175 331-340
• 47 Andrieu J M, Even P, Venet A et al.. Effects of cyclosporin on T-cell subsets in human immunodeficiency virus disease.  Clin Immunol Immunopathol. 1988;  47 181-198
• 48 Towers G J, Hatziioannou T, Cowan S, Goff S P, Luban J, Bieniasz P D. Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors.  Nat Med. 2003;  9 1138-1143
• 49 Rizzardi G P, Harari A, Capiluppi B et al.. Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy.  J Clin Invest. 2002;  109 681-688
• 50 Rizzardi G P, Lazzarin A, Pantaleo G. Potential role of immune modulation in the effective long-term control of HIV-1 infection.  J Biol Regul Homeost Agents. 2002;  16 83-90
• 51 Martin L N, Murphey-Corb M, Mack P et al.. Cyclosporin A modulation of early virologic and immunologic events during primary simian immunodeficiency virus infection in rhesus monkeys.  J Infect Dis. 1997;  176 374-383
• 52 Chapuis A G, Paolo Rizzardi G, D'Agostino C et al.. Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo.  Nat Med. 2000;  6 762-768
• 53 Margolis D, Hossain M, Shaw L, Back D. The addition of mycophenolate mofetil can induce decreases in HIV-1 RNA and intracellular deoxyguanosine triphosphate (Abstract presented at the 5th International Workshop on HIV-1 Drug Resistance, Scottsdale, AZ).  Antivir Ther. 2001;  6(suppl 1) 11
• 54 Hossain M M, Coull J J, Drusano G L, Margolis D M. Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir.  Antiviral Res. 2002;  55 41-52
• 55 Garcia F, Plana M, Arnedo M et al.. Effect of mycophenolate mofetil on immune response and plasma and lymphatic tissue viral load during and after interruption of highly active antiretroviral therapy for patients with chronic HIV infection: a randomized pilot study.  J Acquir Immune Defic Syndr. 2004;  36 823-830
• 56 Calabrese L H, Lederman M M, Spritzler J et al.. Placebo-controlled trial of cyclosporin-A in HIV-1 disease: implications for solid organ transplantation.  J Acquir Immune Defic Syndr. 2002;  29 356-362
• 57 Margolis D, Heredia A, Gaywee J, Oldach D, Drusano G, Redfield R. Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity.  J Acquir Immune Defic Syndr. 1999;  21 362-370
• 58 Heredia A, Amoroso A, Davis C et al.. Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: an approach to suppress R5 strains of HIV-1.  Proc Natl Acad Sci USA. 2003;  100 10411-10416
• 59 Heredia A, Margolis D, Oldach D, Hazen R, Le N, Redfield R. Abacavir in combination with the inosine monophosphate dehydrogenase (IMPDH)-inhibitor mycophenolic acid is active against multidrug-resistant HIV-1.  J Acquir Immune Defic Syndr. 1999;  22 406-407
• 60 Schwarz A, Offermann G, Keller F et al.. The effect of cyclosporine on the progression of human immunodeficiency virus type 1 infection transmitted by transplantation: data on four cases and review of the literature.  Transplantation. 1993;  55 95-103
• 61 Margolis D M, Kewn S, Coull J J et al.. The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA.  J Acquir Immune Defic Syndr. 2002;  31 45-49
• 62 Stallone G, Schena A, Infante B et al.. Sirolimus for Kaposi's sarcoma in renal-transplant recipients.  N Engl J Med. 2005;  352 1317-1323
• 63 Dummer J S, Erb S, Breinig M K et al.. Infection with human immunodeficiency virus in the Pittsburgh transplant population: a study of 583 donors and 1043 recipients, 1981-1986.  Transplantation. 1989;  47 134-140
• 64 Poli F, Scalamogna M, Pizzi C, Mozzi F, Sirchia G. HIV infection in cadaveric renal allograft recipients in the North Italy Transplant Program.  Transplantation. 1989;  47 724-725
• 65 Tzakis A G, Cooper M H, Dummer J S, Ragni M, Ward J W, Starzl T E. Transplantation in HIV + patients.  Transplantation. 1990;  49 354-358
• 66 Erice A, Rhame F S, Heussner R C, Dunn D L, Balfour Jr H H. Human immunodeficiency virus infection in patients with solid-organ transplants: report of five cases and review.  Rev Infect Dis. 1991;  13 537-547
• 67 Bouscarat F, Samuel D, Simon F, Debat P, Bismuth H, Saimot A G. An observational study of 11 French liver transplant recipients infected with human immunodeficiency virus type 1.  Clin Infect Dis. 1994;  19 854-859
• 68 Ahuja T S, Zingman B, Glicklich D. Long-term survival in an HIV-infected renal transplant recipient.  Am J Nephrol. 1997;  17 480-482
• 69 Ragni M V, Bontempo F A, Lewis J H. Organ transplantation in HIV-positive patients with hemophilia [letter; comments].  N Engl J Med. 1990;  322 1886-1887
• 70 Stock P G, Roland M E, Carlson L et al.. Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study.  Transplantation. 2003;  76 370-375
• 71 Roland M E, Adey D, Carlson L L, Terrault N A. Kidney and liver transplantation in HIV-infected patients: case presentations and review.  AIDS Patient Care STDS. 2003;  17 501-507
• 72 Roland M E, Stock P G. Review of solid-organ transplantation in HIV-infected patients.  Transplantation. 2003;  75 425-429
• 73 Roland M CL, Terrault N, Freise C, Hirose R, Rogers R, Stock P. Patient and graft outcomes following solid organ transplantation. Paper presented at: 11th Conference on Retroviruses and Opportunistic Infections February 8-11, 2004 San Francisco, CA;
• 74 Neff G W, Bonham A, Tzakis A G et al.. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease.  Liver Transpl. 2003;  9 239-247
• 75 Prachalias A A, Pozniak A, Taylor C et al.. Liver transplantation in adults coinfected with HIV.  Transplantation. 2001;  72 1684-1688
• 76 Norris S, Taylor C, Muiesan P et al.. Outcomes of liver transplantation in HIV-infected individuals: the impact of HCV and HBV infection.  Liver Transpl. 2004;  10 1271-1278
• 77 Moreno S, Fortun J, Quereda C et al.. Liver transplantation in HIV-infected recipients.  Liver Transpl. 2005;  11 76-81
• 78 Rafecas A, Rufi G, Figueras J et al.. Liver transplantation without steroid induction in HIV-infected patients.  Liver Transpl. 2004;  10 1320-1323
• 79 Vogel M, Voigt E, Schafer N et al.. Orthotopic liver transplantation in human immunodeficiency virus (HIV)-positive patients: outcome of 7 patients from the Bonn cohort.  Liver Transpl. 2005;  11 1515-1521
• 80 Radecke K, Fruhauf N R, Miller M et al.. Outcome after orthotopic liver transplantation in five HIV-infected patients with virus hepatitis-induced cirrhosis.  Liver Int. 2005;  25 101-108
• 81 Honkoop P, Kazemier G, Perenboom R M, van de Ende M E, de Man R A. [Liver transplantation in a HIV-positive patient receiving potent antiretroviral therapy: the first case in The Netherlands].  Ned Tijdschr Geneeskd. 2004;  148 2500-2504
• 82 Polard E, Camus C, Abault A Y et al.. Retransplantation for acute liver failure due to combined antiviral agents in an HIV-HCV coinfected liver transplant recipient.  Transplantation. 2005;  80 1136-1138
• 83 Antoniades C, Macdonald C, Knisely A, Taylor C, Norris S. Mitochondrial toxicity associated with HAART following liver transplantation in an HIV-infected recipient.  Liver Transpl. 2004;  10 699-702
• 84 Lonergan J T, Behling C, Pfander H, Hassanein T I, Mathews W C. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens.  Clin Infect Dis. 2000;  31 162-166
• 85 Tien P C, Grunfeld C. The fatty liver in AIDS.  Semin Gastrointest Dis. 2002;  13 47-54
• 86 Moreno A, Quereda C, Moreno L et al.. High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin.  Antivir Ther. 2004;  9 133-138
• 87 Moreno A, Quereda C, Barcena R. Successful pregnancy after orthotopic liver transplantation in a patient with HIV infection.  N Engl J Med. 2005;  353 2517-2518
• 88 Jain A, Venkataramanan R, Shapiro R et al.. The interaction between anti-retroviral agents and tacrolimus in liver and kidney transplant patients. Paper presented at: American Transplant Congress 2002 Washington, DC;
• 89 Guaraldi G, Cocchi S, Codeluppi M et al.. Role of therapeutic drug monitoring in a patient with human immunodeficiency virus infection and end-stage liver disease undergoing orthotopic liver transplantation.  Transplant Proc. 2005;  37 2609-2610
• 90 Frassetto L, Baluom M, Jacobsen W et al.. Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus-infected liver and kidney transplant recipients.  Transplantation. 2005;  80 13-17
• 91 Vogel M, Voigt E, Michaelis H C et al.. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients.  Liver Transpl. 2004;  10 939-944
• 92 Benhamou Y, Bochet M, Thibault V et al.. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study.  Lancet. 2001;  358 718-723
• 93 Ying C, De Clercq E, Nicholson W, Furman P, Neyts J. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir.  J Viral Hepat. 2000;  7 161-165
• 94 Sulkowski M S, Mast E E, Seeff L B, Thomas D L. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus.  Clin Infect Dis. 2000;  30(suppl 1) S77-S84
• 95 Benhamou Y, Bochet M, Thibault V et al.. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients.  Hepatology. 1999;  30 1302-1306
• 96 Colin J F, Cazals-Hatem D, Loriot M A et al.. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men.  Hepatology. 1999;  29 1306-1310
• 97 Thibault V, Benhamou Y, Seguret C et al.. Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus.  J Clin Microbiol. 1999;  37 3013-3016
• 98 Terrault N A, Carter J T, Carlson L, Roland M E, Stock P G. Outcome of patients with hepatitis B virus and human immunodeficiency virus infections referred for liver transplantation.  Liver Transpl. 2006;  12 801-807
• 99 Ishak K, Baptista A, Bianchi L et al.. Histological grading and staging of chronic hepatitis.  J Hepatol. 1995;  22 696-699
• 100 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA).  MMWR Recomm Rep. 1999;  48 1-59 61-56
• 101 Holly E A, Ralston M L, Darragh T M, Greenblatt R M, Jay N, Palefsky J M. Prevalence and risk factors for anal squamous intraepithelial lesions in women.  J Natl Cancer Inst. 2001;  93 843-849
• 102 Palefsky J M, Holly E A, Ralston M L et al.. Effect of highly active antiretroviral therapy on the natural history of anal squamous intraepithelial lesions and anal human papillomavirus infection.  J Acquir Immune Defic Syndr. 2001;  28 422-428
• 103 Chin-Hong P V, Palefsky J M. Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency virus.  Clin Infect Dis. 2002;  35 1127-1134
• 104 Roland M E, Stock P G. Comprehensive guidelines translate research findings into clinical policy for HIV-infected transplant candidates and recipients.  Enferm Infecc Microbiol Clin. 2005;  23 331-334
• 105 Tien P C. Management and treatment of hepatitis C virus infection in HIV-infected adults: recommendations from the Veterans Affairs Hepatitis C Resource Center Program and National Hepatitis C Program Office.  Am J Gastroenterol. 2005;  100 2338-2354
• 106 Miro J M, Moreno A, Tuset M and the HIV SOT Working Group et al. GESIDA/GESITRA-SEIMC, SPNS and ONT consensus document on solid organ transplant (SOT) in HIV-infected patient in Spain. 2005
• 107 O'Grady J, Taylor C, Brook G. Guidelines for liver transplantation in patients with HIV infection (2005).  HIV Med. 2005;  6(suppl 2) 149-153